• Gilead announces a goal of producing two million treatment courses of remdesivir by December 2020 (with 190,000 available by the end of June 2020), by supplementing its internal manufacturing capacity through partnerships in North America, Europe and Asia. Source
• South Africa, which is home to 30% of Africa’s COVID-19 infections, launches a 2,000- person trial of the Oxford vaccine candidate. Sources 1,2
